Key result
Metabolomic profiles are being investigated as potential predictors for early diagnosis of antiblastic drug-induced cardiotoxicity and cardiovascular damage.
Why the study?
Antiblastic drug-induced cardiomyopathy remains a major cause of morbidity and mortality despite cardioprotective advances, prompting interest in metabolomic profiling to predict cardiotoxicity and cardiac damage.
Metabolomic profiling represents a growing area of interest for the early prediction and management of chemotherapy-induced cardiotoxicity.
Metabolic profiling may aid prediction of chemotherapy cardiotoxicity; hypothesis-generating and requires prospective validation before clinical adoption.
Antiblastic drugs-induced cardiomyopathy remains a relevant cause of morbidity and mortality, during and after chemotherapy, despite the progression in protective therapy against cardiovascular diseases and myocardial function. In the last few decades, many groups of researchers have focused their attention on studying the metabolic profile, first in animals, and, subsequently, in humans, looking for profiles which could be able to predict drug-induced cardiotoxicity and cardiovascular damage. In clinical practice, patients identified as being at risk of developing cardiotoxicity undergo a close follow-up and more tailored therapies. Injury to the heart can be a consequence of both new targeted therapies, such as tyrosine kinase inhibitors, and conventional chemotherapeutic agents, such as anthracyclines. This review aims to describe all of the studies carried on this topic of growing interest.
No takes yet. Share an insight, caveat, or question.
Fazzini et al. (2022) conducted a review in Antiblastic drug-induced cardiomyopathy. Metabolomic profiles was evaluated. Metabolomic profiles are being investigated as potential predictors for early diagnosis of antiblastic drug-induced cardiotoxicity and cardiovascular damage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: